Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00187031 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor
A Phase 2 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT00187031 is a Phase 2 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 37 participants.
The verdict
NCT00187031, a Phase 2 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
In spite of the overall success of treating Wilms tumor, certain patients still have poor clinical outcomes. The sub-optimal outcomes for patients with anaplastic histology and recurrent Wilms tumor warrant the identification of new therapeutic agents. The objective of this trial is to estimate the response rate to two cycles of intravenous topotecan in children with recurrent Wilms tumor of favorable histology that is refractory to standard curative therapy.
Interventions
- DRUG Topotecan, Filgrastim (G-CSF), Pegfilgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2002-11 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00187031
The ClinicalTrials.gov registry entry for NCT00187031 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Topotecan, Filgrastim (G-CSF), Pegfilgrastim is the first listed.
NCT00187031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00187031 about?
NCT00187031 is a clinical study titled "A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor". In spite of the overall success of treating Wilms tumor, certain patients still have poor clinical outcomes. The sub-optimal outcomes for patients with anaplastic histology and recurrent Wilms tumor warrant the identification of new therapeutic agents. The objective of this trial is to estimate the ...
What is the current status of trial NCT00187031?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2002-11. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00187031?
The interventions under investigation include: Topotecan, Filgrastim (G-CSF), Pegfilgrastim (DRUG).
Who is sponsoring clinical trial NCT00187031?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.